News archive

Two teams of prize winners were awarded this year's prize for research into substitute and supplementary methods for animal experiments in research and teaching in Berlin.

Using a liver-on-a-chip model, a team led by Dr. Geraldine Hamilton, scientific director of the start-up company Emulate from Boston, has investigated whether they are able to detect the toxicity of drugs at an early stage.

Prof. Thierry Soldati and his team from the Department of Biochemistry at the University of Geneva infected amoebae and amoeboid-mobile slime fungus cells to test new antibiotics and to reduce animal testing with mice.

According to Dr. Peter Theunissen from the Dutch Medicines Evaluation Board (CBG), in the foreseeable future, much fewer animals are used for the evaluation of the developmental toxicology effects of drugs. On behalf of the government, the CBG monitors the quality of pharmaceuticals and is involved in the preparation of guidelines for the pharmaceutical industry.

Scientists from the Institute of Anatomy and Cell Biology at the Julius Maximilian University Würzburg (JMU) succeeded a step further to complex organoids with blood vessels, immune cells, and connective tissue.

Amyloid fibrils: Different than thought

Thursday, 14 November 2019 12:20

For the first time, a German-American team of scientists has succeeded in isolating and investigating beta-amyloid fibrils from the human brain. These protein fibers are suspected of causing Alzheimer's disease and cerebral amyloid angiopathy.

Tax support for research by companies

Wednesday, 13 November 2019 12:47

In its second and third readings, the German Parliament (Bundestag) passed the "Law on the Introduction of Tax Research Support".

A Dutch team of scientists has used organoids to successfully predict the efficacy of chemotherapy against metastatic colorectal cancer.

The Institute for In Vitro Sciences (IIVS), headquartered in Gaithersburg, Maryland, is a non-profit research and test laboratory dedicated to the worldwide further development of animal-free in vitro methods. InVitro+Jobs spoke with Dr. Erin Hill, co-founder, and president of the IIVS, about the Environmental Protection Agency's goal to completely phase out mammalian toxicity testing by 2035.

Researchers from the Broad Institute of Harvard and MIT at Cambridge have developed a new gene-editing technique that modifies the genetic code more precisely than the CRISPR/Cas9 currently in use. The procedure is called Prime Editing and is expected to be promising for the future therapy of hereditary diseases.